Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 2, 2002 - Issue 4
Submit an article Journal homepage
79
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Challenges in the pharmacotherapy of the epilepsies

Giuliana Gatti Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Piazza Botta 10, 27100 Pavia, Italy. [email protected]
&
Emilio Perucca Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Piazza Botta 10, 27100 Pavia, Italy. [email protected]
Pages 439-442 | Published online: 10 Jan 2014

References

  • Perucca E. Clinical pharmacology and therapeutic use of the new anti-epileptic drugs. Fund. Clin. Pharmacol 15,405–417 (2001).
  • Perucca E. Principles of pharmacotherapy of the epilepsies. In: Diseases of the Nervous System: Clinical Neuroscience and Therapeutic Principles. Asbury AK, McKhann G, McDonald WI, Goadsby PJ, McArthur JC (Eds), Cambridge University Press, Cambridge, UK (2002).
  • Beghi E, Perucca E. The management of epilepsy in the 1990s: Acquisitions, uncertainties and perspectives for future research. DITIF 49,680-694 (1995)
  • Kwan P, Brodie M. Early identification of refractory epilepsy. N Engl. I Med. 342, 314–319 (2000).
  • Perucca E, Beghi E, Dulac 0, Shorvon S, Tomson T Assessing risk to benefit ratio in anti-epileptic drug therapy. Epilepsy Res. 41, 107–139 (2000).
  • Scott RA, Lathoo SD, Sander JW. The treatment of epilepsy in developing countries: Where do we go from here. Bull. World Health Org. 79,344-349 (2001).
  • Meinardi H, Scott RA, Reis R, Sander JW. The treatment gap in epilepsy: The current situation and ways forward. Epilepsia 42, 136–149 (2001).
  • Chiron C, Dumas C, Jambaqué I, Mumford J, Dulac 0. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 26,389-395 (1997).
  • Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: A randomized, prospective study. Epilepsia 38,1270–1274 (1997).
  • Mattson RII, Scheyer RD, Petroff OA, During MJ, Collins TL, Spencer D. Novel methods for studying new anti-epileptic drug pharmacology. Adv Neural 76, 105–112 (1998). itPerucca E. Predicting the response to anti- epileptic drugs: The role of genetic factors. In: Patient Tailored Drug Therapy International Coigns Series 1094 Kaneko S (Ed.), Elsevier, Amsterdam, The Netherlands (2002).
  • Perucca E, Tomson T Monotherapy trials with the new anti-epileptic drugs: Study designs, practical relevance and ethical implications. Epilepsy Res. 33,247–262 (1999).
  • Kilviainen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 15, 217–230 (2001).
  • Brodie MJ, Overstall PW, Giorgi L and the UK Lamotrigine Elderly Study Group. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res. 37, 81–87 (1999).
  • Zahn CA, Morrell MJ, Collins SD, Labiner DM, Yerby MS. Management issues for women with epilepsy. A review of the literature. Neurology15,949–956 (1998).
  • Beghi E, Annegers JE Pregnancy registries in epilepsy. Epilepsia 42,1422–1425 (2001).
  • Besag FMC, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 39,183–187 (1998).
  • Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate—lamotrigine comedication in refractory complex partial seizures. Evidence for a pharmacodynamic interaction. Epilepsia 40,1141–1146 (1999).
  • Brodie MJ, Yuen AWC and 105 Study Group. Lamotrigine substitution study: Evidence for synergism with sodium valproate. Epilepsy Res. 26,423-432 (1997).
  • Deckers CLP, Czuczwar S., Hekster YA etal. Selection of anti-epileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41, 1364–1374 (2000).
  • Walker MC, Sander JWAS. The impact of the new anti-epileptic drugs on the prognosis of epilepsy. Seizure freedom should be the ultimate goal. Neurology 46, 912–914 (1996).
  • Bialer M, Walker MC, Sander JW. Pros and cons for the development of new anti-epileptic drugs. CNS Drugs 16,285–289 (2002).
  • Bialer M, Johannessen SI, Levy RII, Loiseau P, Perucca E. Progress report on new anti-epileptic drugs: a summary of the Sixth Eilat Conference (EILAT Epilepsy Res. (2002, in press)
  • Temkin NR, Jarell AD, Anderson GD. Anti-epileptogenic agents: how close are we? Drugs61, 1045–1055 (2001).
  • Temkin NR. Anti-epileptogenesis and seizure prevention trials with anti-epileptic drugs: metanalysis of controlled trials. Epilepsia 42,515–524 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.